辅助抗PD-1免疫治疗对可切除非黑色素瘤女性患者卵巢功能的影响:前瞻性观察研究
该 national、多中心、前瞻性观察研究纳入17例<45岁接受辅助抗PD-1治疗的可切除III-IV期黑色素瘤女性,中位随访5.1年,评估卵巢功能。结果显示卵巢形态、AFC及AMH无下降,激素水平在生理范围波动;5例治疗后至少生育一子,1例数据截止时妊娠。
要点
- 辅助抗PD-1治疗未观察到卵巢功能不全。
- 卵巢形态、AFC及AMH在治疗期间及治疗后稳定。
- 内分泌免疫毒性患者仍可成功妊娠。
核心结论
- 辅助抗PD-1治疗黑色素瘤未发现治疗相关卵巢功能不全证据,包括发生内分泌毒性者。
研究设计与样本
- 国家多中心前瞻性观察研究,纳入2018至2024年<45岁接受辅助抗PD-1治疗的可切除III-IV期黑色素瘤女性17例,平均年龄28.9岁(范围17-38),中位随访5.1年。
主要发现
- 卵巢形态和AFC在所有时间点保持正常稳定,治疗期间及治疗后AMH未见下降。
- FSH、LH、雌二醇、孕酮和抑制素B水平在生理范围内波动,符合正常月经周期。
- 完成辅助治疗后5例至少生育一子,1例数据截止时妊娠;2例发生内分泌免疫毒性(1型糖尿病和垂体炎),均治疗后受孕。
临床怎么用
- 可为接受辅助抗PD-1治疗且有生育意愿的年轻黑色素瘤女性提供卵巢功能保留的咨询依据。
局限性
- 样本量小(17例),为观察性研究,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment and are increasingly used in the adjuvant and neoadjuvant setting for malignancies such as melanoma, which often affect younger adults. With improving survival, concerns about long-term safety, including potential effects on fertility, are growing. METHODS: We conducted a national, multicenter, prospective observational study of female patients < 45 years treated with adjuvant anti-PD-1 therapy for resectable stage III-IV melanoma from 2018 to 2024. Ovarian function was assessed at baseline and at 3, 6, 12, and 18 months after treatment initiation. Each visit included transvaginal ultrasound for antral follicle count (AFC) and serum analysis of anti-Müllerian hormone (AMH), estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and inhibin-B. RESULTS: Seventeen female patients were enrolled (mean age 28.9 years, range 17-38). Median follow-up was 5.1 years. Ovarian morphology and AFC remained normal and stable at all time points. No decline in AMH was observed during or after treatment. FSH, LH, estradiol, progesterone, and inhibin-B levels fluctuated within physiological ranges consistent with normal menstrual cycling. After completing adjuvant therapy, five patients had at least one child, and one was pregnant at data cut-off. Two patients developed endocrine immune-related toxicity (type 1 diabetes and hypophysitis); both conceived post-treatment. DISCUSSION: This prospective evaluation of ovarian function during and after adjuvant anti-PD-1 therapy in melanoma found no evidence of treatment-related ovarian insufficiency, including in patients with endocrine toxicities. These findings are important for counseling young patients receiving adjuvant therapy who may wish to conceive in the future.
引用
- Pedersen S, Colmorn LB, Ellebaek E, et al. Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study. Eur J Cancer. 2026. PMID: 41713079. doi:10.1016/j.ejca.2026.116584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。